A plant compound sold as a supplement on one idea: that it stands in for a growth protein the brain uses to keep nerve cells alive. Recorded effects span memory, mood, body fat and hearing-nerve repair, all in animals. None has been tested in a person, so every claimed benefit and hazard sits at the lowest evidence grade. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma pyridoxal 5'-phosphate | 30–110 nmol/L | The compound blocks the enzyme that clears it; excess damages sensory nerves |
| ALT and AST | ALT 10–26 U/L (men), 10–19 U/L (women); AST 10–26 U/L | Catechol flavones are cleared hepatically; detects liver strain early |
| Fasting glucose | 75–86 mg/dL | Rodent data show glucose lowering; detects additive low blood sugar |
| Fasting insulin | 2–5 µIU/mL | The primary readout of the claimed metabolic benefit |
| HbA1c | 4.8–5.3% | Confirms whether any glucose change holds over three months |
| hs-CRP | Below 0.5 mg/L | Tests the anti-inflammatory claim made for the compound |
| Estradiol; total testosterone in men | No established target on this compound; the change from the individual's own baseline is what is tracked | The compound activates the estrogen receptor, so a shift matters more than an absolute value |
| Complete blood count with differential | No functional target specific to this compound; the change from the individual's own baseline within conventional limits is what is tracked | A broad safety net where no toxicity data exist |
Cadence: Full panel at baseline before a first dose, then at 12 weeks, at 6 months if use continues, then every 6 to 12 months. Vitamin B6 and fasting glucose add a 4-week check and a further check at any dose change.